Position in RLMD
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$6,716,400
+$5,894,505 QoQ
Shares Held
965,000
+309.8% QoQ
Ownership
0.920%
of shares outstanding
% of Portfolio
0.97%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2022
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in RLMD Over Time
Shares Held
Position Value (USD)
Derivatives in RLMD
reported options exposure · as of Dec 31, 2022CallValue
$0
CallShares
0
PutValue
$822,244
PutShares
235,600
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Sio Capital Management, LLC holds $315,732,064 across 42 Biotechnology names. RLMD ranks #18 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
370,045 | $31,054,176 | |
| 2 | CORT |
Corcept Therapeutics Inc
|
674,759 | $27,199,535 | |
| 3 | TYRA |
Tyra Biosciences, Inc.
|
605,439 | $23,188,313 | |
| 4 | CELC |
Celcuity Inc.
|
193,843 | $22,125,240 | |
| 5 | ABVX |
Abivax S.A.
|
135,800 | $15,121,330 | |
| 6 | VIR |
Vir Biotechnology, Inc.
|
1,498,620 | $13,427,635 | |
| 7 | SION |
Sionna Therapeutics, Inc.
|
294,340 | $11,800,090 | |
| 8 | RAPP |
Rapport Therapeutics, Inc.
|
366,809 | $11,477,453 |
All Filings in RLMD
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,716,400 | 965,000 | Shares | Sole | 2026-05-14 | |
| 2022-12-31 | $822,244 | 235,600 | Put | Sole | 2023-02-13 | |
| 2022-12-31 | $821,895 | 235,500 | Shares | Sole | 2023-02-13 | |
| 2022-09-30 | $22,441,524 | 606,200 | Put | Sole | 2022-11-14 | |
| No filing history on record for this holder in this stock. | ||||||